Industry Relations Council
8735 W. Higgins Road Suite 300 Chicago, IL 60631
Tel: (847)375-6340 Email: info@itns.org

Search our Site

Industry Relations Council (IRC)

The ITNS Industry Relations Council is available to organizations that support the goals and mission of ITNS and provide products or services used in the area of transplantation. Membership is for one year. It is a nonvoting membership with benefits extended to a single corporate-designated representative. Membership is available at an associate or executive level. Read about the benefits of joining the IRC and apply today.

 

Executive Level

 

 AstellasTransplant RGB

 

Astellas Pharma US, Inc.
1 Astellas Way
Northbrook, IL 60062
www.astellas.com 

Astellas Pharma US, Inc. is the headquarters for the Americas for Astellas Pharma (Toyko). Astellas is a pharmaceutical company dedicated to improving the health of people around the world by providing innovative and reliable products in the areas of cardiology, dermatology, infectious disease, oncology, transplant and urology.

Atara Bio1 logo 300x300

Atara Biotherapeutics, Inc.
611 Gateway Blvd, Suite 900
South San Fracisco, CA 94080
www.atarabio.com 


Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s lead candidate is a T-cell immunotherapy being investigated for the treatment of patients with Epstein-Barr virus associated post-transplant lymphoproliferative disease (EBV+PTLD).

View clinical trial information

View another clinical trial

Veloxis logo RGB 300dpi

 

Veloxis Pharmaceuticals
1001 Winstead Drive, 3rd floor, Suite 310
Cary, North Carolina 27513
www.veloxis.com

Veloxis Pharmaceuticals (Veloxis) is a specialty pharmaceutical company focused on the development and commercialization of a novel product for the prevention of organ rejection in kidney transplant patients. All clinical studies including two Phase III trials, have successfully been completed and a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in December 2013 seeking approval for the marketing and sale. Veloxis is commited to ensuring access to ENVARSUS XR regardless of a patient's insurance or financial situation. Patient Financial Support Resources